Alphabet-Backed Isomorphic Labs Raises $5 Billion for AI Drug Discovery

Isomorphic Labs, the London-based AI drug discovery company founded by Nobel laureate and former Google DeepMind CEO Demis Hassabis, has closed a landmark $5 billion Series C funding round—one of the largest investments in AI-driven pharmaceutical research.

The round was co-led by Greenoaks and Sequoia Capital, with participation from all existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. Isomorphic’s parent company, Alphabet, also made a “significant investment” through its GV and CapitalG funds. Investors reportedly oversubscribed the round.

The new capital will help scale the company’s proprietary AI drug design engine, IsoDDE (Isomorphic Labs Drug Design Engine). The platform brings together foundational simulation models to identify and refine molecules with drug-like properties across multiple therapeutic areas.

The company has reported positive preclinical results in its internal oncology and immunology programs, as well as in partnered research initiatives. Isomorphic aims to advance its first drug candidates toward clinical trials by the end of 2026.

The funding follows a $2.1 billion Series B closed in May 2026, reflecting growing investor confidence in AI-designed medicines. Drug discovery startups have collectively raised a record $23.2 billion in 2026 to date.

Source: SiliconANGLE – Alphabet’s Isomorphic Labs raises $5B to accelerate drug discovery with AI (November 17, 2026)

Move to the category:

Leave a Reply

Your email address will not be published. Required fields are marked *